Women's health advocates say they want to expand the availability of morning-after pills to convenience stores as new state ...

<li /> 46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with ...

The voluble billionaire discusses his mission to transform health care, why Kamala lost, the problem with Bluesky, and much ...

Over the past forty-five years the United States has experienced deepening economic divisions between the rich and poor. The ...

Drug companies in the U.S. face few restraints on what to charge for their products. A bipartisan bill would penalize those companies that sell their drugs at higher prices than the average of the ...

The FDA is likely to approve the first treatment for smoldering multiple myeloma but pass on a new option relapsed/refractory DLBCL, after votes by its Oncologic Drugs Advisory Committee.

LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK)2.8 million injections of repackaged ...

The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive ...

The Itovebi-based regimen is approved for the treatment of adults with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer in the United ...

The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer, compared with palbociclib and fulve ...

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared ...